TV-46000

DRUG2 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Schizophrenia

Phase 3

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

CompletedNCT03503318

Teva Branded Pharmaceutical Products R&D, Inc.Schizophrenia

Start: 2018-04-27End: 2020-12-03Updated: 2023-03-10

A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia

CompletedNCT03893825

Teva Branded Pharmaceutical Products R&D, Inc.Schizophrenia

Start: 2019-04-17End: 2021-12-02Updated: 2022-12-07

Related Papers

Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.

2025-11-21

Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies

CNS Drugs2025-07-291 citations

TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia.

2024-10-093 citations

Long-term Safety, Tolerability, and Effectiveness of TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), in Patients With Schizophrenia (SHINE)

CNS Spectrums2024-10-01

A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.

2024-07-028 citations

Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.

2023-11-0222 citations

Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia.

2023-03-1115 citations